[go: up one dir, main page]

SG11201606101WA - Compositions and methods for treating and preventing macular degeneration - Google Patents

Compositions and methods for treating and preventing macular degeneration

Info

Publication number
SG11201606101WA
SG11201606101WA SG11201606101WA SG11201606101WA SG11201606101WA SG 11201606101W A SG11201606101W A SG 11201606101WA SG 11201606101W A SG11201606101W A SG 11201606101WA SG 11201606101W A SG11201606101W A SG 11201606101WA SG 11201606101W A SG11201606101W A SG 11201606101WA
Authority
SG
Singapore
Prior art keywords
compositions
treating
methods
macular degeneration
preventing macular
Prior art date
Application number
SG11201606101WA
Inventor
Abraham Scaria
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of SG11201606101WA publication Critical patent/SG11201606101WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J50/00—Circuit arrangements or systems for wireless supply or distribution of electric power
    • H02J50/10—Circuit arrangements or systems for wireless supply or distribution of electric power using inductive coupling
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J50/00—Circuit arrangements or systems for wireless supply or distribution of electric power
    • H02J50/40—Circuit arrangements or systems for wireless supply or distribution of electric power using two or more transmitting or receiving devices
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
    • H02J7/0013—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries acting upon several batteries simultaneously or sequentially
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
    • H02J7/0042—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries characterised by the mechanical construction
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
    • H02J7/0042—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries characterised by the mechanical construction
    • H02J7/0045—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries characterised by the mechanical construction concerning the insertion or the connection of the batteries
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
    • H02J7/02—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries for charging batteries from AC mains by converters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
    • H02J7/34—Parallel operation in networks using both storage and other DC sources, e.g. providing buffering
    • H02J7/35—Parallel operation in networks using both storage and other DC sources, e.g. providing buffering with light sensitive cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Power Engineering (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Liquid Crystal Substances (AREA)
SG11201606101WA 2014-02-06 2015-02-06 Compositions and methods for treating and preventing macular degeneration SG11201606101WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461936797P 2014-02-06 2014-02-06
PCT/US2015/014872 WO2015120309A1 (en) 2014-02-06 2015-02-06 Compositions and methods for treating and preventing macular degeneration

Publications (1)

Publication Number Publication Date
SG11201606101WA true SG11201606101WA (en) 2016-08-30

Family

ID=52589781

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201606101WA SG11201606101WA (en) 2014-02-06 2015-02-06 Compositions and methods for treating and preventing macular degeneration

Country Status (14)

Country Link
US (2) US20170007719A1 (en)
EP (1) EP3102246B1 (en)
JP (1) JP6719381B2 (en)
KR (1) KR102234695B1 (en)
CN (3) CN111068072A (en)
AU (4) AU2015213770A1 (en)
BR (1) BR112016017817A2 (en)
CA (1) CA2938828A1 (en)
IL (1) IL247116B (en)
MX (2) MX2016010215A (en)
RU (1) RU2703145C2 (en)
SG (1) SG11201606101WA (en)
TW (1) TWI687225B (en)
WO (1) WO2015120309A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201606101WA (en) 2014-02-06 2016-08-30 Genzyme Corp Compositions and methods for treating and preventing macular degeneration
KR101685532B1 (en) * 2016-04-26 2016-12-13 한국프라임제약주식회사 A VEGFR fusion protein
CA3054942A1 (en) * 2017-03-17 2018-09-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression
KR102205830B1 (en) * 2017-10-26 2021-01-21 주식회사 큐로진생명과학 Pharmaceutical Composition for Treating Macular Degeneration Containing AAV Including cDNA of Soluble VEGFR Variant
CA3091250A1 (en) * 2018-02-14 2019-08-22 Generation Bio Co. Non-viral dna vectors and uses thereof for antibody and fusion protein production
EP3863605A4 (en) * 2018-10-11 2022-10-26 Decibel Therapeutics, Inc. Aav1 vectors and uses thereof for treatment of otic indications
CN113952473A (en) * 2020-07-21 2022-01-21 英斯培瑞有限公司 Compositions and methods for treating ocular diseases
CN119656336A (en) * 2023-09-21 2025-03-21 成都弘基生物科技有限公司 Application of recombinant adeno-associated virus in preparation of medicine for treating angiogenesis-associated eye diseases

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
DE10399031I1 (en) 1987-08-28 2004-01-29 Health Research Inc Recombinant viruses.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
FR2658432B1 (en) 1990-02-22 1994-07-01 Medgenix Group Sa MICROSPHERES FOR THE CONTROLLED RELEASE OF WATER-SOLUBLE SUBSTANCES AND PREPARATION METHOD.
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
CA2115742A1 (en) 1991-08-20 1993-03-04 Ronald G. Crystal Adenovirus mediated transfer of genes to the gastrointestinal tract
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5763270A (en) 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
PT833934E (en) 1995-06-15 2005-02-28 Crucell Holland Bv PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIVRUS INTENDED FOR GENETIC THERAPY
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US5622856A (en) 1995-08-03 1997-04-22 Avigen High efficiency helper system for AAV vector production
US7034009B2 (en) * 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US6004797A (en) 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
US6048551A (en) 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
IL147270A0 (en) 1999-07-02 2002-08-14 Genentech Inc Fusion peptides comprising a peptide ligand domain and a multimerization domain
ES2308989T3 (en) 1999-08-09 2008-12-16 Targeted Genetics Corporation INCREASE IN THE EXPRESSION OF A NUCLEOTIDIC SEQUENCE HETEROLOGY FROM RECOMBINANT VIRECT VECTORS CONTAINING A SEQUENCE FORMING INTRACATENARY BASE PAIRS.
AU2001257611A1 (en) 2000-04-28 2001-11-12 Avigen, Inc. Polynucleotides for use in recombinant adeno-associated virus virion production
AU6972301A (en) 2000-06-01 2001-12-11 Univ North Carolina Duplexed parvovirus vectors
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
NZ535100A (en) 2002-03-20 2008-04-30 Univ Florida RAAV vector compositions and methods for the treatment of choroidal neovascularization
US20100144038A1 (en) 2003-03-04 2010-06-10 Masato Miyake Composition And Method For Increasing Efficiency Of Introduction Of Target Substance Into Cell
DK2277996T3 (en) 2003-05-21 2014-10-20 Genzyme Corp PROCEDURES FOR MAKING PREPARATIONS OF RECOMBINANT AAV VIRUSES THAT IN THE MAIN CASE ARE FREE OF EMPTY CAPSIDES
CN100476110C (en) * 2003-08-04 2009-04-08 邱则有 Cavity formwork component for cast-in-situ concrete
CN1997386B (en) 2004-07-30 2012-05-30 瑞泽恩制药公司 Methods of treating type I diabetes by blocking VEGF-mediated activity
DE602005021811D1 (en) 2004-09-13 2010-07-22 Genzyme Corp MULTI-MORE CONSTRUCTS
DE602004031786D1 (en) * 2004-11-26 2011-04-21 Inst Nat Sante Rech Med MODULATION OF RETINAL PIGMENTED EPITHELIAL PERMEATION BY INHIBITION OF VEGFR-1
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
US20090105245A1 (en) * 2006-12-21 2009-04-23 Bingaman David P Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
WO2009042162A2 (en) 2007-09-25 2009-04-02 Genzyme Corporation Compositions and methods for inhibiting interleukin pathways
EP2227553A4 (en) 2007-11-30 2011-01-19 Scarab Genomics Llc Lac expression system
BRPI0908496A2 (en) * 2008-02-20 2019-01-15 Genzyme Corp angiogenesis inhibition
WO2009105690A2 (en) 2008-02-21 2009-08-27 Targeted Genetics Corporation Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
WO2010019263A2 (en) 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
JP5956331B2 (en) 2009-06-16 2016-07-27 ジェンザイム・コーポレーション Improved purification method for recombinant AAV vectors
SG183929A1 (en) 2010-03-29 2012-10-30 Univ Pennsylvania Pharmacologically induced transgene ablation system
US9102718B2 (en) 2010-04-30 2015-08-11 Lpath, Inc. Anti-S1P antibody treatment of patients with ocular disease
TWI702955B (en) * 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 Treatment of amd using aav sflt-1
CA2909706C (en) 2013-04-17 2023-02-14 Genzyme Corporation Use of an il17 inhibitor for treating and preventing macular degeneration
SG11201606101WA (en) * 2014-02-06 2016-08-30 Genzyme Corp Compositions and methods for treating and preventing macular degeneration

Also Published As

Publication number Publication date
JP6719381B2 (en) 2020-07-08
US20220288232A1 (en) 2022-09-15
BR112016017817A2 (en) 2017-10-10
US20170007719A1 (en) 2017-01-12
CN111068072A (en) 2020-04-28
IL247116A0 (en) 2016-09-29
MX2016010215A (en) 2016-11-15
AU2015213770A1 (en) 2016-09-01
TWI687225B (en) 2020-03-11
EP3102246B1 (en) 2020-03-25
MX2023011453A (en) 2023-10-18
KR20160110523A (en) 2016-09-21
JP2017506230A (en) 2017-03-02
AU2019203413B2 (en) 2021-07-15
AU2021250986B2 (en) 2025-02-06
CN120131999A (en) 2025-06-13
CN106163573A (en) 2016-11-23
AU2021250986A1 (en) 2021-11-18
CA2938828A1 (en) 2015-08-13
AU2025203206A1 (en) 2025-05-29
IL247116B (en) 2020-06-30
RU2016135771A (en) 2018-03-14
EP3102246A1 (en) 2016-12-14
WO2015120309A1 (en) 2015-08-13
TW201542217A (en) 2015-11-16
RU2703145C2 (en) 2019-10-15
RU2016135771A3 (en) 2018-10-15
US12483047B2 (en) 2025-11-25
AU2019203413A1 (en) 2019-06-06
KR102234695B1 (en) 2021-04-02

Similar Documents

Publication Publication Date Title
IL278004A (en) Methods and compositions for treating aging-associated conditions
IL246791A0 (en) Compositions and methods for treating ocular diseases
AP2017009674A0 (en) Methods and compositions for treating ulcers
IL251759A0 (en) Compositions and methods for treating insomnia
PT3200815T (en) Methods and compositions for treating cancer
PL3261644T3 (en) Compositions and methods for treating retinal degradation
LT3189074T (en) Compositions and methods for treating and preventing inflammation
SG11201606101WA (en) Compositions and methods for treating and preventing macular degeneration
SG10201708547YA (en) Compositions and methods for treating and preventing macular degeneration
IL251616A0 (en) Methods and compositions for treating and preventing muscle wasting disorders
ZA201606673B (en) Compositions and methods for treating neurodegenerative diseases
PT3220908T (en) Compositions and methods for treating endometriosis
IL253220A0 (en) Compositions and methods for treating glaucoma
EP3164132A4 (en) Methods and compositions for treating diseases and conditions
ZA201703771B (en) Compositions and methods for treating hyperkalemia
ZA201605109B (en) Compositions and methods for treating neutropenia
IL252394A0 (en) Methods of preventing, reducing or treating macular degeneration
EP3139744A4 (en) Methods and compositions for treating and preventing tinnitus
PT3519050T (en) Compositions and methods for treating ophthalmic conditions
IL252707B (en) Compositions and methods for treating diseases and conditions
EP3194446A4 (en) Compositions and methods for treating fibrosis
HK1229638A1 (en) Methods and compositions for treating and preventing tinnitus
GB201521083D0 (en) Compositions for treatment and methods thereof
GB201407949D0 (en) Compositions and methods for treating biofilms
AU2015901334A0 (en) Methods and compositions for preventing and/or treating cataracts